Name | Title | Contact Details |
---|
Clementia is a biopharmaceutical company that is focused on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease. Our lead program is palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
PAIGE is being built by a dedicated team of Machine Learning experts and pathologists from the leading cancer center in the US and experienced business leadership.
Dance Biopharm is a private company focused on developing novel inhaled formulations of medicines to treat diabetes and other serious chronic diseases.
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients` lives using the company`s industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington`s disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.
Diosynth is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.